U.S. Hepatitis C Market

Published: October 2011
No. of Pages: 75
Price: $ 6000


This research service covers the U.S. hepatitis C (HCV) market from 2008 to 2016, with 2010 as the base year.  Included are products on the market, products in development, and patient and revenue forecasts.  Market challenges, drivers, and restraints are identified and assessed.  The market is segmented by classes of drug: interferons, protease inhibitors, nucleotide polymerase inhibitors, non-nucleotide polymerase inhibitors, NS5a's, and other classes. Included are examinations of therapeutic candidates on the market and in the HCV late-stage pipeline.

Browse All: Healthcare Market Research Reports

Executive Summary 4
Market Overview 10
Total Market
• External Challenges: Drivers and Restraints 16
• Forecasts and Trends 26
• Demand Analysis 39
• Market Share and Competitive Analysis 41
Peginterferon alfa and Ribavirin Segment Breakdown 54
Protease Inhibitor Segment Breakdown 60
The Last Word 66
Appendix 70